Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Net Margin (2016 - 2026)

Cytosorbents filings provide 15 years of Net Margin readings, the most recent being 59.53% for Q4 2025.

  • On a quarterly basis, Net Margin rose 2316.0% to 59.53% in Q4 2025 year-over-year; TTM through Dec 2025 was 22.12%, a 3684.0% increase, with the full-year FY2025 number at 22.12%, up 3609.0% from a year prior.
  • Net Margin hit 59.53% in Q4 2025 for Cytosorbents, down from 33.42% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 20.25% in Q2 2025 to a low of 150.42% in Q3 2022.
  • Median Net Margin over the past 5 years was 65.47% (2023), compared with a mean of 62.91%.
  • The widest YoY moves for Net Margin: up 7816bps in 2022, down -8916bps in 2022.
  • Cytosorbents' Net Margin stood at 86.32% in 2021, then soared by 91bps to 8.16% in 2022, then tumbled by -725bps to 67.31% in 2023, then dropped by -23bps to 82.69% in 2024, then rose by 28bps to 59.53% in 2025.
  • The last three reported values for Net Margin were 59.53% (Q4 2025), 33.42% (Q3 2025), and 20.25% (Q2 2025) per Business Quant data.